Genmab — Juni 2017

gentogen

https://myelomaresearchnews.com/2016/09/21/minimal-residual-disease-in-myeloma-suggested-as-clinical-trial-endpoint-but-experts-disagree/

Bulder

FDA kommer til at gi' sig på et tidspunkt https://www.myelomacrowd.org/minimal-residual-disease-negativity-becomes-new-end-point-myeloma-therapy/

bibob

Det er sikkert Bulder. De kan ikke komme uden om Dara.

E_L

Not sure it this NCT was posted here already, Janssen mo
ves fast - NCT03177460 A Pilot Presurgical Study of Daratumumab in Men With High-Risk Localized Prostate Cancer - https://clinicaltrials.gov/ct2/show/NCT03177460?term=daratumumab+OR+ofatumumab&lup_s=06%2F08%2F2017&rank=1

JKY_VH

jo den mener jeg vi har set

Bulder

Her er interviewet med Moreau om Cassiopeia. Han siger at de lukker Q1 2017 og data i 2018. https://www.youtube.com/watch?v=wttCv152AK4&t=19s

GeorgeBest

EL - why would MD Andersson do this prostate cancer study as monotherapy? Wouldn't it be better to combine dara with an approved prostate cancer drug like Xtandi?

E_L

I am not sure, but this is on patients that are already scheduled to have prostatectomy -my guess is that they are just trying to get extra information out of that patient group?

GeorgeBest

Thanks

Bulder

Formålet er ikke at udrydde canceren i prostata, men at få tumoren til at skrumpe så meget, at det bliver lettere at operere.

GeorgeBest

Tak Bulder. Men monotherapi er svær. Det så vi med Carina.

Bulder

Nu kan de så begynde at koncentrere sig om Genmab http://www.investor.jnj.com/releaseDetail.cfm?ReleaseID=1029759

Thomas

Nogen der kan forklare mig hvordan Commerzbanks Turbo Bull Genmab fungerer? Og evt anbefalinger eller det modsatte af produktet. Jeg har styr på risiko